Molecular Vision 2008; 14:2321-2332 <>
Received 19 May 2008 | Accepted 30 November 2008 | Published 12 December 2008

Clinical and genetic findings in Hungarian patients with X-linked juvenile retinoschisis

B. Lesch,1 V. Szabó,1 M. Kánya,3,4 G.M. Somfai,1 R. Vámos,1 B. Varsányi,1 Zs. Pámer,2 K. Knézy,1 Gy. Salacz,1 M. Janáky,5 M. Ferencz,1 J. Hargitai,1 A. Papp,1 Á. Farkas1

1Department of Ophthalmology, Semmelweis University, Budapest, Hungary; 2Department of Ophthalmology, Medical Faculty of the University of Pécs, Pécs, Hungary; 31st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; 4OBIK Medical Biotechnology Innovation Center Inc., Budapest, Hungary; 5Department of Ophthalmology, Medical Faculty of the University of Szeged, Szeged, Hungary

Correspondence to: Balázs Lesch, Semmelweis University, Department of Ophthalmology, Mária Street 39, Budapest, 1085, Hungary; Phone: 36208258525; FAX: 3613179061; email:


Purpose: To determine clinical phenotypes, examine the age dependency of X-linked juvenile retinoschisis (XLRS), and identify mutations in the retinoschisis1 gene (RS1) in 13 Hungarian (Caucasian) families with this disease.

Methods: This study included 72 members in 13 families. Complete ophthalmological examinations, including optical coherence tomography (OCT) and full-field and multifocal electroretinography (ERG), were performed on 20 affected males, 13 female carriers, and 27 healthy controls. The patients were divided into two age groups (Group I <25 years and Group II >25 years), retrospectively, to assess the possible effects of age. Correlations among genotype, age, best corrected visual acuity (BCVA), OCT, and ERG results were analyzed. A modified classification scheme was done to identify the different phenotypes of the disease. In each of the 72 family members and 100 age-matched male controls, all exons and introns of RS1 were amplified by polymerase chain reaction (PCR) and directly sequenced.

Results: Foveal retinoschisis was detected in 25 eyes (62.5%) of patients by funduscopy, and in 29 eyes (72.5%) by OCT, while macular lamellar schisis was recognizable only by OCT in 30 eyes (75%) of patients. Foveal thickness (FT) and total macular volume were significantly increased in younger (Group I) patients only. For patients younger than 26 years, large inner nuclear central cysts were observable by OCT, while after 26 years, foveas were atrophic. White flecks and dots, which were like that seen in fundus albipunctatus, were detected in both eyes of one patient. In both patient groups, characteristically decreased b-waves of standard combined ERG were recorded without any significant difference between the patient groups. The BCVA and ERG parameters of all patients and the OCT of younger patients were significantly worse (p<0.05) than those of age-matched controls. A significant difference between the two age groups was found in case FT, total macular volume, and amplitudes of rod b-wave only. Moderate negative correlation (r=-0.54, p<0.001) was detected between age and FT, while only low negative correlation (r=-0.33, p<0.05) was detected between age and standard combined b-wave amplitudes of full-field ERG. BCVA LogMAR did not show any obvious correlation with age (r=-0.14, p=0.39) or with the type of mutation. Nine different mutations were identified in 25 male patients and 31 female carriers of 13 families: six known and one novel missense mutation (c.575C>T, p.Pro192Leu), one insertion mutation (c.579dupC, p.Ile194Hisfs29ext43), and one frameshift, causing splice site mutation (c.78+1G>C) were detected. These mutations were absent in the 100 age-matched male control samples.

Conclusions: Foveal cystic schisis was found more often by OCT than by funduscopy (+10%), while flat macular lamellar schisis was recognizable only by OCT. Advancing age inversely influenced the size of cavities (FT), and standard combined b-wave amplitudes of full-field ERG, while BCVA, response density, and implicit times of multifocal electroretinography did not show any obvious correlation with age. The atrophic stage of the disease was observable after 26 years of age. The lesions that appeared to be indicative of fundus albipunctatus were proven to be palisades between the splitted retinal layers. Our modified classification scheme was helpful in assessing the prevalence of disease types. In these Hungarian patients, one novel and eight known mutations were detected. The distribution of mutations in RS1 was different to that reported in the literature, because the greatest number of different mutations was in exon 6 instead of exon 4. Two mutation hot spots were found: between c.418–422 in exon 5 and between c.574–579 in exon 6. Genotype-phenotype correlation was not demonstrable.


X-linked juvenile retinoschisis (XLRS; OMIM: 312700) is one of the most common X-linked recessively inherited, bilateral, progressive vitreoretinal dystrophies. Limited almost exclusively to males, the incidence is between 1:5,000 and 1:25,000 [13]. Macular changes are present in almost all cases [4]. In the fundi, radially oriented intraretinal foveomacular cysts are seen in a spoke-wheel configuration, with the absence of foveal reflex in most cases (Figure 1A). In addition, approximately half of cases have bilateral peripheral retinoschisis in the inferotemporal part of the retina (Figure 1B) [4]. Aside from the typical fundus appearance, strabismus, nystagmus, axial hyperopia, defective color vision (red-green dyschromatopsia) and foveal ectopy can be present [4,5]. The most important complications were vitreous hemorrhage, retinal detachment, and neovascular glaucoma [1,4,6]. The diagnosis of the disease is most often made in boys aged 5–10 years, who may also exhibit symptoms of uncorrectable visual disturbance and reading difficulties [4].

Optical coherence tomography (OCT) images can be variable depending on the disease stage. The cysts are located in different layers of the retina (Figure 1C), namely the nerve fiber (NFL), ganglion cell (GCL), inner nuclear (INL), outer plexiform (OPL), outer nuclear (ONL) and photoreceptor layers (PRL) [79]. In the course of time the coalescing cysts form a large central cavity (Figure 1C), which can pass into a nonspecific macular atrophy (Figure 1D) [3,5,10,11]. Disease severity and progression are highly variable.

Full-field electroretinograms (ERGs) of the affected individuals are characterized by predominant reduction of standard combined b-wave amplitude (negative-type ERG: b-wave to a-wave ratio less than or equal to 1) in the dark-adapted eye (Figure 1E) [2,12]. The a-wave may also be reduced with disease progression due to the increasing retinal pigment epithelium (RPE) atrophy [4,13]. The response densities of multifocal ERG (mfERG) diminish mainly in the central rings (Figure 1F) and the implicit times are extended. Thus, ERG is a useful diagnostic method in almost all cases [2].

XLRS is caused by mutation in the RS1 gene (localization: Xp22.2-p22.1, GenBank AF014459), which was identified by positional cloning in 1997 (Figure 2) [14]. This is the only known gene to be associated with XLRS so far [15]. RS1 has six exons and encodes a 224 amino acid (AA) secretable extracellular adhesion protein, called retinoschisin (RS1), which is primarily present in photoreceptors and in bipolar cells [6]. It may be involved in cellular adhesion and cell-cell interactions on membrane surfaces [16]. Retinoschisin includes a secretory leader sequence (LS; 23 AA), an Rs1 domain (Rs1D; 39 AA), a highly conserved discoidin domain (a main structural feature of RS; 157 AA), and a C-terminal segment (5 AA) [2,1619]. The discoidin domain is essential for the normal development of the retina, and if functional RS1 is lacking, schisis develops in different retinal layers [14,15].


Informed consent was obtained from all participants after a full explanation of the nature and possible consequences of the study. All studies were conducted in accordance with the tenets of the Declaration of Helsinki. Molecular genetic examinations were approved by the Ethics Committee for Human Genome Research of Semmelweis University.

Patient and control groups

In all, 72 members (mean age ±SD: 32.6±19.1 years) in 13 Hungarian families were involved in the present study (Figure 3). Of the 72 family members, 20 male patients (mean age ±SD: 24.5±16.8 years) and 13 asymptomatic female carriers (mean age±SD: 37.7±13.3 years) took part in all clinical examinations: visual acuity tests, indirect ophthalmoscopy, slit lamp biomicroscopy, full-field and mfERG, and OCT. The patients were divided into two groups (Group I aged <25 years and Group II aged >25 years), retrospectively, on the basis of our observation that the cystic form of the disease manifest before 26 years of age, while the atrophic form occurs after 26 years (Appendix 1, Figure 4). In this way we could examine the possible functional effects of morphological changes and the effects of age. All 72 family members participated in molecular genetic examinations.

A control group of 27 healthy age-matched normal subjects (mean age ±SD: 20.1±8.2 years) was examined using the same clinical protocol. To confirm the pathogenetic effects of the identified mutations a control group of 100 healthy age-matched normal male subjects (mean age±SD: 22.4±9.3 years) was examined using the same molecular genetic protocol. BCVA logarithm of the Minimum Angle of Resolution=logarithm of the reciprocal of Snellen’s fraction (LogMAR units) was 0.0 in all controls, and no visual disturbances were found.

Clinical examinations

All study participants underwent standard ophthalmological examinations. BCVA was determined using the Snellen chart then converted to LogMAR units. Dilated indirect ophthalmoscopy of the posterior pole and the periphery was performed with fundus photography.

Optical coherence tomography

OCT was performed in both eyes of the family members using six 6 mm long OCT scans centered on the fovea by a Stratus OCT device (Carl Zeiss Medical Inc., Dublin, CA). The foveal thickness (FT) was measured manually in the center of the fovea with the more accurate caliper technique, while total macular volume (TMV) was calculated automatically by the built-in software of the device. To determine eccentric fixation, we displayed the FT on a color-coded map; the center of the map showed the fixation point (Figure 1C-D). To assess the prevalence of the different phenotypes of the disease, we modified and extended the Prenner “Classification scheme for XLRS” (Table 1) [20].


For each subject, ERG was performed (RetiPort ERG system, Roland Consult, Wiesbaden, Germany) using corneal “jet” contact lens electrodes, according to International Society for Clinical Electrophysiology of Vision (ISCEV) standards. Amplitudes and implicit times of scotopic and photopic full-field ERG responses were measured, and the ratio of standard combined b- and a-wave amplitudes was calculated. During mfERG the central 60° diameter part of the retina was stimulated monocularly by 61 hexagons shown on a 21” CRT display, under photopic conditions. Amplitudes and implicit times of the b-waves (P1) of first order kernels (FOK) were measured. For each patient, response densities (RD; nV/deg2) in the five concentric rings were calculated. All the amplitudes and implicit times were compared with the mean values±SD of the normal age-matched controls.

Genetic examination

Genomic DNA was extracted from peripheral blood leucocytes using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany). PCR was performed using standard protocols in a Thermo Hybaid PxE thermal cycler (Thermo Hybaid, Franklin, MA) with oligonucleotide primers published previously by the RS Consortium [15]. The amplicons were analyzed on 1% agarose gels and stained with ethidium bromide and purified using Roche High Pure PCR Purification Kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s protocol. Exons and the flanking intronic regions of RS1 was sequenced by direct nucleotide sequencing using the Big Dye Terminator Cycle-Sequencing v3.1 Kit (Applied Biosystems, Foster City, CA) and run on an automated sequencer (ABI PRISM® 310 Genetic Analyzer, Perkin Elmer™; Applied Biosystems). The results were compared with the reference sequence of the X-linked retinoschisis sequence variation database (dmd).

Statistical analysis

To assess significant changes between patients and control persons, we performed ANOVA (one-way ANOVA) followed by Newman-Keuls post hoc analysis. Significance was accepted at the p<0.05 level. Correlations (Spearman rank) were calculated between age, BCVA, OCT, and ERG parameters. For statistical analysis the Statistica 6.0 (Statsoft, Inc., Tulsa, OK) and Excel (Microsoft® Corp.) software packages were used.


Clinical examination

Table 1, Table 2, Table 3, Appendix 1, and the figures show the results of the clinical and molecular genetic examinations. Although impairment of BCVA was significant (p<0.05) in patients (Appendix 1) compared with the normal age-matched controls, there was no significant difference between the two patient groups. Foveal ectopy were detected in 17 eyes of 12 male patients. During a one-year follow-up only four eyes of two male patients (family 1 IV:2, family 2 III:1) showed improvement in BCVA from 0.42±0.17 to 0.27±0.13 (mean±SD). All XLRS patients had macular abnormalities seen by indirect funduscopy. Eleven of 20 patients (55%) had typical bilateral foveal schisis, 25 of 40 eyes (62.5%) had typical microcystic findings (spoke-wheel pattern; Figure 1A), and 15 eyes (37.5%) had nonspecific atrophic macular degeneration. In addition to the macular changes, peripheral retinoschisis was found only in seven eyes (17.5%) in the inferotemporal part of the retina (Figure 1B). White flecks and dots, characteristic of fundus albipunctatus, were found in two eyes of patient III:3 in family 3, and this feature was associated with the biggest foveal retinoschisis and huge bullous peripheral retinoschisis (Figure 1B and Figure 5). The distance between white flecks and dots (calculated by fundus photography) was equal to the distance between palisades connecting the splitted retinal layers (measured by OCT).

Optical Coherence Tomography

Presence of cysts (any kind) was evident in 31 eyes (77.5%), 29 eyes (72.5%) had foveal cystic schisis, and 30 eyes (75%) had macular lamellar schisis. The nonspecific atrophic form in the macula (without any cystic changes) was found in 9 eyes (22.5%=type 6+7; Table 1). The most common appearance of the disease was the combined foveal cystic and macular lamellar schisis (type 3, 23 eyes, 57.5%). BCVA impaired gradually from type 1 to type 6.

The most extended foveal schisis with large, low-reflective cysts—surrounded perifoveally by many smaller ones—was located in the INL (Figure 1C). The INL was always affected in the cystic stage of the disease. Besides these, another deeper schisis was demonstrated in the photoreceptor layer (PRL), and some small cysts were seen in the GCL. Schisis was detected as follows: in 13 eyes (32.5%) in the GCL, INL, and PRL; in 13 eyes (32.5%) in the GCL and INL; in four eyes (10%) in the INL only; and in one eye (2.5%) in the INL and PRL (Table 2). The worst BCVA values were detected when cysts were located in the GCL, INL, and PRL (Group A). In case affectedness of PRL in group A, significant impairment of BCVA values were detected compared with group B (p<0.05).

The FT was significantly increased in the macula in age-group I (mean of FT±SD: 566.9±324.9, p<0.001), but there was no significant increase in age-group II (mean of FT±SD: 210.9±191.8) as compared with control subjects. TMV was significantly increased in group I (mean of FT±SD: 10±5.8, p<0.001), but there was no significant change in group II (mean of FT±SD: 6.12±1.26), compared with the controls. Significant difference (p<0.001) was detected between OCT parameters (FT, TMV) of the two patient groups. According to FT results (and similarly for TMV), the age after which the cystic form of the disease disappeared and the atrophic form occurs was 26 years (Figure 4).


All the amplitudes of scotopic (mainly standard combined b-waves) and photopic responses of full-field ERG were significantly decreased (p<0.05) in both patient groups compared with values for controls (Appendix 1). Significant difference (p<0.05) between the two age groups was found for the rod b-wave amplitudes only. The prevalence of negative type ERG was 50% (20 eyes) for all patients, but was more common (70%) in the younger group I (Figure 6B). There was no significant difference between the standard combined b-wave implicit times of both patient groups and the control values. Apart from the significantly decreased implicit times of standard combined a-waves (p<0.05), the implicit times of the other measured scotopic and photopic responses were significantly increased in both patient groups compared with the controls (p<0.05). There was no significant difference between the implicit times of younger and older patient groups.

RD of mfERG in patients was significantly reduced (p<0.001) in all rings, but mainly in the central part of the examined retinal area (corresponding to the region of foveal schisis) compared with the controls (Figure 7). There was no significant difference between the RD of younger and older patient groups. Implicit times of patients were significantly increased (p<0.05) only in the peripheral part of the examined retinal area (rings 3–5) compared with the controls. There was no significant difference between the implicit times of younger and older patient groups.

Female carriers were found to have no visual disturbances. Their BCVA (LogMAR units) were 0.0. In addition, their FT, TMV, and ERG results were within the normal age-matched ranges.

Genetic examination

In 25 patients (mean age±SD: 26.9 years±18.5 years) and 31 female carriers (mean age±SD: 39.7 years±17.7 years) nine different mutations (eight known and one novel) were identified by molecular genetic examination (Figure 2, Table 3). Mutations, which included missense (85.7+1.79%), small frameshift insertions (7.14%), and splice site mutations (7.14%), were detected in 100% of the patients and carriers. Most of the mutations (92.85%) were localized in the conservative discoidin domain, while the RS1 domain was affected in only 7.14%. The greatest number of different mutations (four different) was found in exon 6, while exon 5 was the most frequently (49.99%) affected part of the RS1 gene. The most commonly found mutation (23.21%) was the c.421C>T (p.Arg141Cys) missense mutation (exon 5). Molecular testing revealed a novel missense mutation (c.575C>T, p.Pro192Leu) in exon 6 of family 7. In addition, two previously reported frameshift causing mutations were found: a splice site mutation (c.78+1G>C) in intron 2 of family 2 (7.14%) and an insertion mutation (c.579dupC) in exon 6 of family 11 (7.14%). In the II:2 patient of family 4, two different mutations were found: a de novo (c.421C>T, Arg141Cys) mutation and a maternal inherited one (c.574C>T, Pro192Ser). The pathogenic effects of these mutations were confirmed by excluding their presence in 100 normal male control DNA samples.


Moderate negative correlation (r=-0.54, p<0.001) was detected between age and FT. When the stages were analyzed separately, correlation was low negative for the cystic stage (r=-0.31, p=0.14) and barely negative for the atrophic stage (r=-0.24, p=0.38) stage (Figure 4). Low negative correlation (r=-0.33, p<0.05) was detected between age and standard combined b-wave amplitudes of full-field ERG (Figure 6A). On the other hand BCVA LogMAR did not show any obvious correlation with age (r=-0.14, p=0.39), or with the type of mutation (Figure 8).


The BCVA of patients was significantly impaired from childhood and, contrary to the results of Pimenides et al., [21] further significant impairment was not detectable with age. Although foveal abnormalities were found in all patients using both indirect funduscopy and OCT, foveal cystic schisis was more often found (+10%) by the OCT, and appeared to mainly occur in the INL and PRL retinal layers. Aside from the presence of cysts in GCL and INL, significant impairment of BCVA was detected if photoreceptors (PRL) were affected also. The flat macular lamellar schisis was recognizable only by OCT. Presence of cysts was evident in more than 3/4 of the eyes, while the nonspecific atrophic form in the macula was found in almost 1/4 of the eyes. The high overall prevalence of the cystic form in these results is undoubtedly due to the relatively young age of our patients (mean 24.5±16.6 years). The most common phenotype of the disease was the association of foveal cysts and macular lamellar schisis (type 3). The prevalence of peripheral retinoschisis was found to be lower than generally reported in the literature [4]. White flecks and dots, characteristic of fundus albipunctatus, were associated with the biggest foveal and peripheral retinoschisis. Lesions that are like that seen in fundus albipunctatus are a known, uncommon fundus appearance in XLRS [22]. Our calculations confirmed that white lesions seemed to be identical to palisades visible by OCT between the splitted retinal layers.

Patients’ OCT images differed greatly, and a large interocular and intrafamilial variability was found. The time-course of the disease can be characterized by the OCT parameters (Figure 4). This study is the first to present the exact time of changing from the cystic to atrophic stage of the disease. Before 26 years of age, large inner nuclear central cysts (with significantly elevated FT and TMV) were characteristic (Figure 1C). After 26 years of age a nonspecific foveal and perifoveal atrophy with unchanged parafoveal retinal thickness was more common (Figure 1D). In older age the whole macula was markedly atrophic.

Regarding the change from the cystic to atrophic stage (after 26 years), a moderate negative correlation was detectable between age and FT; but within each stage there was only low and little negative correlation with age (Figure 4). Excluding the remarkable FT change about 26 years of age the aforedescribed results showed a rather limited age dependency of FT alterations. Examining the possible functional effects of the morphological changes found by OCT between the younger and older patient groups, there were no significant differences in BCVA, in amplitudes and implicit times of full-field (except the rod b-wave amplitudes) and mfERGs. The lack of correlation between OCT and BCVA was probably due to inability to fixate and the common eccentric fixation. As with other reports, we found the changing of central macular region visible by OCT was not accompanied by further visual impairment [12,23].

In two boys (family 1 IV:2, 12 years of age; family 2 III:1, 7 years of age) improvement of BCVA (three lines on the Snellen chart) was detected during a one-year follow-up, but without any notable structural changes (OCT), or functional improvement (ERG) of the retina. This was probably due to more efficient use of the ectopic parafoveal retina, and would occur only in young patients as a result of the plasticity of the developing visual system.

While previous research has demonstrated that RS1 is synthesized mainly in and secreted from the inner segment of photoreceptors [6,2426], Takada et al. identified in healthy mouse retina that RS1 mRNA was expressed in the ganglion cells first, and later in all remarkable cells locally in the outer layers of the retina [26]. This molecular mechanism explains why retinoschisis may affect several different layers of the retina [26]. In agreement with the latest publications we found retinoschisis mainly in the INL (Müller and bipolar cells) and in the PRL, using OCT [7,9,12,27]. The dysfunctional, defective RS1 may accumulate in these layers, both intracellular and extracellular layers, leading to cysts and schisis [3,21]. In cases of nonspecific foveal atrophy, electrophysiological and molecular genetic examinations are needed to confirm the diagnosis.

Nonspecifically all the amplitudes of scotopic and photopic responses of full-field ERG were significantly decreased in both patient groups compared with the controls. The only appropriate clinical sign to confirm the diagnosis of XLRS was the pronouncely decreased standard combined b-wave amplitudes, and in advanced cases negative type full-field ERGs (in 50% of patients). Significant difference between full-field ERG responses of the two patient groups was found in case rod b-wave amplitudes only. Standard combined b-wave amplitudes of full-field ERG showed a low negative correlation with age, while BCVA LogMAR did not show any obvious correlation with age or mutation type (Figure 8).

The mainly centrally decreased P1 amplitudes of mfERG probably indicate the lack of functioning cells in the central part of the foveal schisis, while the mainly peripherally delayed implicit times may be caused by the functionally damaged but still living cells. Previous results, based on ERG examinations, found Müller cells to be primary locations of the disease [28]. Recent results demonstrate that the mfERG (FOK) P1-waves originate mainly from ON- and OFF-bipolar cells, with a smaller contribution from cone photoreceptors [28]. Thus bipolar cells seem to be affected rather than Müller cells in which, furthermore, no RS immunoreactivity was detected [24,26]. Our abnormal ERG responses also suggest that the retinal damage affects mainly the INL and the PRL layers, where the biggest schisis was found by OCT and where, normally, the RS1 can be detected in the greatest amount [12,24,25]. Flat schisis and functional impairment was detected by OCT and mfERG in a greater part of the retina than would have been expected by funduscopy.

To identify patients with uncertain diagnosis and carriers without any symptoms, molecular genetic examinations are necessary (90% certainty) [29]. On the basis of previous genetic examinations, most of the mutations are missense mutations and localized to exons 4–6 of RS1 within the discoidin domain (dmd) [2]. Exons 1–3 tend to have mainly translation-truncating nonsense mutations [15].

This article is the first study to estimate the genetic background of patients with XLRS in Hungary. All the tested patients and carriers were found to have RS1 coding or splice site mutations. Most of the mutations were found to be localized in the conservative discoidin domain, which caused protein misfolding and finally retention of RS1 in the endoplasmic reticulum [18]. The remaining mutations were localized in the RS1 domain, which interfered with the normal oligomerization of RS1 [18]. Mutations in the leader sequence (not found in our study) prevented the translocation of the polypeptide chain across the endoplasmic reticulum membrane as part of the secretion process [18]. In each case the mutant RS1 was unable to function as an extracellular cell-adhesion protein.

Of the nine different mutations found, the c.421C>T missense mutation (exon 5) was detected most frequently. That a de novo mutation (c.421C>T) was found in patient II:2 of family 4 together with the already known disease-causing variant (c.574C>T, inherited from his mother), illustrates the remarkable new mutation rate of RS1 and the high mutation heterogeneity of the disease. Although the aforedescribed case with simultaneous presence of two mutations and the consequent two AAs substitution led to pronounced change in the tertiary structure of the RS1 (based on the CBS CPH model), neither the clinical condition nor the examination results were affected more than in those cases with separate presence of these two mutations. It is presumed the two mutations led to intracellular degradation of the RS1 even separately [21,30]. Considering that female carriers are unaffected, it seems that the absence of a functional RS1, rather than the presence of a mutant protein, was responsible for retinoschisis in affected males [31].

We highlight the fact that a novel missense mutation (c.575C>T) was found in family 7. Although missense, insertion, and splice site mutations have also been identified, no genotype-phenotype correlation could be detected. The relatively low number of our samples, the intracellular degradation and lack of secretion of mutant RS1 (loss of protein function) could explain why phenotypes are independent of the position or type of mutation [3,21,30]. The great phenotype variability in the case of the same mutation within one family, or between two eyes of the same person, presumably reflects the influence of other factors or genes [32].

Contrary to the data of the Retinoschisis database (dmd; exon 4: 42.7%; exon 5: 16.3%; exon 6: 26.9%), the frequency of various types of mutations per exons and introns were different in these Hungarian patients (exon 4: 11.1%; exon 5: 33.3%; exon 6: 44.4%; and intron 2: 11.1%). Two mutation hot spots were found: between c.418–422 in exon 5 and between c.574–579 in exon 6. Almost 70% of the mutations were within this part of RS1.

Although XLRS is one of the most frequent causes of juvenile macular degeneration, it is still underdiagnosed and often misdiagnosed. Serious visual deterioration can be prevented by regular follow-up and surgical intervention in case of sudden retinal complications. Molecular genetic examinations are of particular importance to identify carriers without any symptoms and timely genetic counseling may help in family planning decisions. Although there is no current therapy for the disease, the successful gene therapy performed in mice brings hope for the future [27,31,33].

Appendix 1. Clinical data of members


We thank Andreas Gal, István Peták, and Hanno Bolz for providing the opportunity to sequence the RS1 gene, and we thank the patients and their families for their kind cooperation in the study.


  1. Mooy CM, Van Den Born LI, Baarsma S, Paridaens DA, Kraaijenbrink T, Bergen A, Weber BH. Hereditary X-linked juvenile retinoschisis: a review of the role of Müller cells. Arch Ophthalmol. 2002; 120:979-84. [PMID: 12096974]
  2. Hiriyanna K, Singh-Parikshak R, Bingham EL, Kemp JA, Ayyagari R, Yashar BM, Sieving PA. Searching for genotype-phenotype correlations in X-linked juvenile retinoschisis. In: Anderson RE, La Vail MM, Hollyfield JG, eds. New Insights into Retinal Degenerative Diseases. New York: Plenum Publishers; 2001;45–53.
  3. Wang T, Waters CT, Rothman AM, Jakins TJ, Römisch K, Trump D. Intracellular retention of mutant retinoschisin is the pathological mechanism underlaying X-linked retinoschisis. Hum Mol Genet. 2002; 11:3097-105. [PMID: 12417531]
  4. Tantri A, Vrabec TR, Cu-Unjieng A, Frost A, Annesley WH, , Jr Donoso LA. X-linked retinoschisis: A clinical and molecular genetic review. Surv Ophthalmol. 2004; 49:214-30. [PMID: 14998693]
  5. McKibbin M, Booth AP, George NDL. Foveal ectopia in X-linked retinoschisis. Retina. 2001; 21:361-6. [PMID: 11508883]
  6. Grayson C, Reid SN, Ellis JA, Rutherford A, Sowden JC, Yates JR, Farber DB, Trump D. Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri–Rb1 cells. Hum Mol Genet. 2000; 9:1873-9. [PMID: 10915776]
  7. Eriksson U, Larsson E, Holmström G. Optical coherence tomography in the diagnosis of juvenile X-linked retinoschisis. Acta Ophthalmol Scand. 2004; 82:218-23. [PMID: 15043546]
  8. Minami Y, Ishiko S, Takai Y, Kato Y, Kagokawa H, Takamiya A, Nagaoka T, Kinouchi R, Yoshida A. Retinal changes in juvenile X linked retinoschisis using three dimensional optical coherence tomography. Br J Ophthalmol. 2005; 89:1663-4. [PMID: 16299154]
  9. Brucker AJ, Spaide RF, Gross N, Kancnik J, Noble K. Optical coherence tomography of X-linked retinoschisis. Retina. 2004; 24:151-2. [PMID: 15076957]
  10. Stanga PE, Chong NHV, Reck AC, Hardcastle AJ, Holder GE. Optical coherence tomography and electrophisiology in X-linked juvenile retinoschisis associated with a novel mutation in the XLRS1 gene. Retina. 2001; 21:78-80. [PMID: 11217940]
  11. Ozdemir H, Karacorlu S, Karacorlu M. Optical coherence tomography findings in familial foveal retinoschisis. Am J Ophthalmol. 2004; 137:179-81. [PMID: 14700666]
  12. Apushkin MA, Fishman GA, Janowicz MJ. Correlation of optical coherence tomography finings with visual acuity and macular lesions in patients with x–linked retinoschisis. Ophthalmology. 2005; 112:495-501. [PMID: 15745780]
  13. Miyake Y, Shiroyama N, Ota I, Horiguchi M. Focal macular electroretinogram in X-linked congenital retinoschisis. Invest Ophthalmol Vis Sci. 1993; 34:512-5. [PMID: 8449671]
  14. Sauer CG, Gehrig A, Warneke-Wittstock R, Marquardt A, Ewing CC, Gibson A, Lorenz B, Jurklies B, Weber BH. Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet. 1997; 17:164-70. [PMID: 9326935]
  15. Retinoschisis Consortium. Functional implications of the spectrum of the mutations found in 234 cases with X-linked juvenile retinoschisis (XLRS). Hum Mol Genet. 1998; 7:1185-92. [PMID: 9618178]
  16. Shinoda K, Ohde H, Ishida S, Inoue M, Oguchi Y, Mashima Y. Novel 473-bp deletion in XLRS1 gene in a Japanese family with X-linked juvenile retinoschisis. Graefes Arch Clin Exp Ophthalmol. 2004; 242:561-5. [PMID: 14986011]
  17. Wu WWH, Molday RS. Defective discoidin domain structure, subunit assembly, and endoplasmic reticulum processing of retinoschisin are primary mechanisms responsible for X-linked retinoschisis. J Biol Chem. 2003; 278:28139-46. [PMID: 12746437]
  18. Wu WWH, Wong JP, Kast J, Molday RS. RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer. J Biol Chem. 2005; 280:10721-30. [PMID: 15644328]
  19. Molday RS. Focus on molecules: Retinoschisin (RS1). Exp Eye Res. 2007; 84:227-8. [PMID: 16600216]
  20. Prenner JL, Capone A Jr Ciaccia S, Takada Y, Sieving PA, Trese MT. Congenital X-linked retinoschisis classification system. Retina. 2006; 26:S61-4. [PMID: 16946682]
  21. Pimenides D, George NDL, Yates JRW, Bradshaw K, Roberts SA, Moore AT, Trump D. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005; 42:e35-35. [PMID: 15937075]
  22. Schooneveld van MJ. Miyake Y. Fundus albipunctatus-like lesion in juvenile retinoschisis. Br J Ophthalmol. 1994; 78:659-61. [PMID: 7918299]
  23. Sikkink SK, Biswas S, Parry NRA, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007; 44:225-32. [PMID: 17172462]
  24. Molday LL, Hicks D, Sauer CG, Weber BHF, Molday RS. Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. Invest Ophthalmol Vis Sci. 2001; 42:816-25. [PMID: 11222545]
  25. Reid SN, Yamashita C, Farber DB. Retinoschisin, a photoreceptor-secreted protein, and its interaction with bipolar and Müller cells J Neurosci 2003; 23:6030–40 [PMID: 12853421]
  26. Takada Y, Fariss RN, Tanikawa A, Zeng Y, Carper D, Bush R, Sieving PA. A retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. Invest Ophthalmol Vis Sci. 2004; 45:3302-12. [PMID: 15326155]
  27. Zeng Y, Takada Y, Kjellstrom S, Hiriyanna K, Tanikawa A, Wawrousek E, Smaoui N, Caruso R. bush RA, Sieving PA. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci. 2004; 45:3279-85. [PMID: 15326152]
  28. Piao CH, Kondo M, Nakamura M, Terasaki H, Miyake Y. Multifocal electroretinograms in X-linked retinoschisis. Invest Ophthalmol Vis Sci. 2003; 44:4920-30. [PMID: 14578418]
  29. Sieving PA, Yashar BM, Ayyagari R. Juvenile retinoschisis: a model for diagnostic testing of x–linked ophthalmic disease. Trans Am ophthalmol soc 1999;97:451–464. Am J Ophthalmol. 2000; 129:833 [PMID: 10927013]
  30. Wang T, Zhou A, Waters CT, O’Connor E, Read RJ, Trump D. Molecular pathology of X-linked retinoschisis: mutations interfere with retinoschisin secretion and oligomerisation. Br J Ophthalmol. 2006; 90:81-6. [PMID: 16361673]
  31. Min SH, Molday LL, Seeliger MW, Dinculescu A, Timmers AM, Janssen A, Tonagel F, Tanimoto N, Weber BH, Molday RS, Hauswirth WW. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x–linked juvenile retinoschisis. Mol Ther. 2005; 12:644-51. [PMID: 16027044]
  32. Eksandh LC, Ponjavic V, Ayyagari R, Bringham EL, Hiriyanna KT, Andreasson S, Ehinger B, Sieving PA. Phenotypic expression of juvenile X-linked retinoschisis in swedish families with different mutations in the XLRS1 gene. Arch Ophthalmol. 2000; 118:1098-104. [PMID: 10922205]
  33. Molday LL, Min SH, Seeliger MW, Wu WW, Dinculescu A, Timmers AM, Janssen A, Tonagel F, Hudl K, Weber BH, Hauswirth WW, Molday RS. Disease mechanisms and gene therapy in a mouse model for X-linked retinoschisis. Adv Exp Med Biol. 2006; 572:283-9. [PMID: 17249585]